Accumulating evidence has revealed the link between the microbiota and various human diseases. Advances in high-throughput sequencing technologies have identified some consistent disease-associated microbial features, leading to the emerging concept of microbiome-based therapeutics. However, it is also becoming clear that there are considerable variations in the microbiota among patients with the same disease. Variations in the microbial composition and function contribute to substantial differences in metabolic status of the host via production of a myriad of biochemically and functionally different microbial metabolites. Indeed, compelling evidence indicates that individuality of the microbiome may result in individualized responses to microbiome-based therapeutics and other interventions. Mechanistic understanding of the role of the microbiota in diseases and drug metabolism would help us to identify causal relationships and thus guide the development of microbiome-based precision or personalized medicine. In this review, we provide an overview of current efforts to use microbiome-based interventions for the treatment of diseases such as cancer, neurological disorders, and diabetes to approach precision medicine.

유자의 이용성을 높이기 위해 유자펙틴 추출물을 첨가한 요구르트를 제조하여 이화학적 특성을 평가하였다. 본 연구에서 추출된 유자펙틴 추출물의 uronic acid 함량은 53.93%였다. 유자펙틴 추출물 첨가 요구르트의 이화학적 특성 실험에 따르면 실험군의 pH는 4.3으로 나타났으며 실험군의 유산균 수는 식품공전에 명시된 요구르트 제조 기준에 적합하였다. 정상유동 특성의 경우 유자펙틴 추출물 첨가 요구르트의 n값은 1보다 낮은 범위(n=0.33~0.44)에 있어 shearthinning 유체 특성이 있었다. 점조도 지수, 겉보기 점도의 경우 대조군보다 모든 유자펙틴 추출물 첨가 요구르트가 유의적으로 높았다. 동적 점탄성의 경우 저장탄성률(G